Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 06/05/2025 at 14:30, 9 months 20 days ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival

Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF

published on 06/02/2025 at 14:35, 9 months 23 days ago

Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025

Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF

published on 06/02/2025 at 14:35, 9 months 23 days ago

Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025

Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE

published on 06/02/2025 at 14:30, 9 months 23 days ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026

BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF

published on 05/29/2025 at 14:35, 9 months 27 days ago

Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model

Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF

published on 05/29/2025 at 14:35, 9 months 27 days ago

Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA

Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE

published on 05/29/2025 at 14:30, 9 months 27 days ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress

Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF

published on 05/15/2025 at 14:05, 10 months 10 days ago

Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections

Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF

published on 05/15/2025 at 14:05, 10 months 10 days ago

Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments

Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE

published on 05/15/2025 at 14:00, 10 months 10 days ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens

Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex

Published on 03/26/2026 at 00:40, 3 hours 57 minutes ago

Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 4 hours 7 minutes ago

Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 9 hours 22 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 15 hours 7 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 15 hours 7 minutes ago

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification

View all ACCESSWIRE

Published on 03/26/2026 at 01:05, 3 hours 32 minutes ago

Blokees Announces Upgrade Brand Mission at 2026 Global Partner Conference
Published on 03/25/2026 at 20:00, 8 hours 37 minutes ago

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 8 hours 56 minutes ago

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 9 hours 7 minutes ago

AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 9 hours 11 minutes ago

EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia

View all EQS

Published on 03/25/2026 at 18:53, 9 hours 43 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:53, 9 hours 44 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 10 hours 6 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 10 hours 6 minutes ago

Performance soutenue des Investissements et déploiement actif de la stratégie
Published on 03/25/2026 at 18:06, 10 hours 31 minutes ago

LNA SANTE : Résultats Annuels 2025

View all LES ECHOS COMFI WIRE

News